-
1Academic Journal
Authors: N. V. Dmitrieva, I. N. Petukhova, Z. V. Grigorievskaya, N. S. Bagirova, I. V. Тereshchenko, E. D. Grigorievsky, Н. В. Дмитриева, И. Н. Петухова, З. В. Григорьевская, Н. С. Багирова, И. В. Терещенко, Е. Д. Григорьевский
Source: Siberian journal of oncology; Том 17, № 3 (2018); 88-93 ; Сибирский онкологический журнал; Том 17, № 3 (2018); 88-93 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2018-17-3
Subject Terms: онкологические больные, Gram-negative bacteria, Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa, polymyxin В, cancer patients, MDR-грамотрицательные микроорганизмы, полимиксин В
File Description: application/pdf
Relation: https://www.siboncoj.ru/jour/article/view/769/542; Григорьевская З.В., Петухова И.Н., Багирова Н.С., Шильникова И.И., Терещенко И.В., Григорьевский Е.Д., Дмитриева Н.В. Нозокомиальные инфекции у онкологических больных: проблема нарастающей резистентности грамотрицательных микроорганизмов. Сибирский онкологический журнал. 2017; 16 (1): 91–97. doi:10.21294/1814-4861-2017-16-1-91-97.; Григорьевская З.В., Петухова И.Н., Дьякова С.А., Дмитриева Н.В. Эпидемиология внутрибольничных инфекций в онкологическом стационаре, вызванных высокорезистентными (XDR) штаммами А. baumannii. Сибирский онкологический журнал. 2016; 15 (3): 62–66. doi:10.21294/1814-4861-2016-15-3-62-66.; Дмитриева Н.В., Петухова И.Н., Багирова Н.С., Григорьевская З.В., Дьякова С.А., Терещенко И.В., Соколова Е.Н. Распространенность нозокомиальных микроорганизмов в онкологической клинике. Клиническая лабораторная диагностика. 2016; 61 (9): 619–620.; Evans M.E., Feola D.J., Rapp R.P. Polymixin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999; 33: 9607.; Дмитриева Н.В., Петухова И.Н., Громова Е.Г. Сепсис. Избранные вопросы диагностики и лечения. М.: АБВ-пресс, 2018. 161–202.; Zavascki A.P., Goldani L.Z., Li J., Nation R.L. Polymyxin B for the treatment of multidrug- resistant pathogens: a critical review. J Antimicrob Chemother. 2007; 60: 1206–121.; Garg S.K., Singh O., Juneja D., Tyagi N., Khurana A.S., Qamra A., Motlekar S., Barkate H. Resurgence of Polymyxin B for MDR/XDR Gram-Negative Infections: An Overview of Current Evidence. Crit Care Res Pract. 2017; 2017: 3635609. doi:10.1155/2017/3635609.; Tascini C., Menichetti F., Bozza S., Del Favero A., Bistoni F. Evaluation of the activities of two-drug combinations of rifampicin, polymyxin B and ampicillin/sulbactam against Acinetobacter baumannii. J Antimicrob Chemother. 1998 Aug; 42 (2): 270–1.; Yoon J., Urban C., Terzian C., Mariano N., Rahal J.J. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2004 Mar; 48 (3): 753–7.; Manikal V.M., Landman D., Saurina G., Oydna E., Lal H., Quale J. Endemic carbapenem- resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis. 2000; 31: 101–6.; Bratu S., Tolaney P., Karumudi U., Quale J., Mooty M., Nichani S., Landman D. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymixin B and othere agents. J Antimicrob Chemother. 2005; 56: 128–32.; Landman D., Bratu S., Alam M., Quale J. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin. B. J Antimicrob Chemother. 2005; 55: 954–7.; Ouderkirk J.P., Nord J.A., Turett G.S., Kislak J.W. Polymyxin B nephrotoxicitry and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother. 2003 Aug; 47 (8): 2659–62.; Sobieszczyk M.E., Furuya E.Y., Hay C.M., Pancholi P., Della-Latta P., Hammer S.M., Kubin C.J. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram- negative respiratory tract infections. J Antimicrob Chemother. 2004; 54: 566–9.; Holloway K.P., Rouphael N.G., Wells J.B., King M.D., Blumberg H.M. Polymyxin B and doxycycline use in patients with multidrugresistant Acinetobacter baumannii infections in the intensive care unit. Ann Pharmacother. 2006; 40: 1939–45.; Zavascki A.P., Barth A.L., Fernandes J.F., Moro A.L., Gonçalves A.L., Goldani L.Z. Reappraisal of Pseudomonas aeruginosa hospital-acquired pneumonia mortality in the era of metallo-β-lactamase-mediated multidrug resistance: a prospective observational study. Crit Care. 2006; 10: R114.; Pereira G.H., Muller P.R., Levin A.S. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B. Diagn Microbiol Infect Dis. 2007; 58: 235–40.; Ostronoff M., Ostronoff F., Sucupira A., Souto Maior A.P., Caniza M., Florêncio R., Domingues M.C., Calixto R., Matias K. Multidrug-resistant Pseudomonas aeruginosa infection in neutropenic patients successfully treated with a combination of polymyxin B and rifampin. Int J Infect Dis. 2006; 10: 339–40.; Crusio R., Rao S., Changawala N., Paul V., Tiu C., van Ginkel J., Chapnick E., Kupfer Y. Epidemiology and outcome of infections with carbapenem-resistant gram-negative bacteria treated with Polymyxin Bbased combination therapy. Scandinavian Journal of Infectious Diseases. 2014; 46 (1): 1–8.; Li J., Nation R.L., Turnidge J.D., Milne R.W., Coulthard K., Rayner C.R., Paterson D.L. Colistin: re-emerging antibiotic for multidrugresistant Gram-negative bacterial infections. Lancey Inbfect Dis. 2006; 6: 589–60.; Falagas M.E., Kasiakou S.K. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006; 10: R27.; Evagelopoulou P., Katsaros A., Myrianthefs P., Karatzas S., Boutzouka E., Fildissis G., Baltopoulos G. Colistin and rhabdomyolysis: a causative agent or an innocent bystander. Intensive Care Med. 2007; 33: 556–7.; Kazy Z., Puho E., Czeizei A.E. Parenteral polymyxin B treatment during pregnancy. Reprod Toxicol. 2005; 20: 181–2.; https://www.siboncoj.ru/jour/article/view/769